The global skin cancer treatment market size was estimated to be USD 10.73 billion in 2023 and is expected to reach at USD 26.65 billion by 2034 with a CAGR of 8.62% during the forecast period 2024-2034. Growing prevalence of skin cancer, rising awareness regarding the disease, increasing demand for skin cancer therapeutic products, surge in research & development activities, growing supportive initiative by government for rising awareness of skin cancer, rising drug approvals of innovative skin cancer therapeutics by regulatory agencies, and increasing launch of advanced treatment options are some of the key factors boosting the market growth.
Increasing launch of advanced treatment options is predicted to boost the market growth during the forecast period. A notable trend in the skin cancer treatment market involves the growing utilization of targeted and immunotherapy medications. Chemotherapy and radiation therapy are associated with several adverse effects. Consequently, there is a rising inclination among patients to select immunotherapy and targeted therapy medications. Moreover, targeted therapy drugs offer improved effectiveness in the treatment of skin cancer. For instance, in May 2022, Labcorp, a prominent worldwide life sciences firm, has introduced a novel assay designed to aid in determining suitable treatment choices for melanoma. This innovative test allows for the evaluation of Lymphocyte-activation gene 3 (LAG-3) expression levels through immunohistochemistry (IHC) analysis of tumor tissue. LAG-3 represents a target for immune-oncology and has shown tangible positive outcomes in treating melanoma patients. The assay is applicable for employment in both patient care and treatment as well as in clinical trial settings.
By indication, melanoma was the highest revenue-grossing segment in the global skin cancer treatment market in 2023 owing to rising prevalence of melanoma, increasing awareness regarding skin cancer among population, surge in technological advancement in the healthcare sector, and growing regulatory approvals. For instance, in January 2022, Immunocore has obtained United States Food and Drug Administration (FDA) clearance for KIMMTRAK (tebentafusp-tebn) to treat adult patients with unresectable or metastatic uveal melanoma (mUM) who are HLA-A*02:01-positive. Additionally, non-melanoma is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for surgical procedures & radiation therapy, surge in introduction of immunotherapy drugs against non-melanoma type of skin cancer, rising accessibility of therapeutic drugs for the treatment of non- melanoma, and growing research activities by key market players.
By therapy, immunotherapy was the highest revenue-grossing segment in the global skin cancer treatment market in 2023 owing to the efficacy of immunotherapy & a reduced risk of adverse effects, surge in number of product launches of immunotherapy drugs, and increasing approvals of novel immunotherapies by regulatory bodies. For instance, in March 2022, Nivolumab and Relatlimab-Rmbw (commercially known as Opdualag by Bristol-Myers Squibb Company) have gained the endorsement of the US FDA for treating unresectable or metastatic melanoma in patients aged 12 years and older, covering both adults and pediatric individuals. Additionally, radiation therapy is predicted to grow at fastest CAGR during the forecast period owing to the rising usage in treatment of squamous cell skin cancers and growing technological advancements in radiation therapy.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global skin cancer treatment market in 2023 owing to the ease of availability of drugs in hospital pharmacy and growing number of hospitals with hospital pharmacies. Additionally, online platforms is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of online platforms for buying pharmaceuticals, a rise in public awareness of these platforms, and growing initiatives by leading market players. For instance, in January 2022, SkinCure Oncology has directed its attention toward establishing a comprehensive approach to delivering Image-Guided Superficial Radiotherapy (Image-Guided SRT). They have introduced GentleCure.com, a platform dedicated to consumer health education, which presents well-founded treatment choices for basal cell (BCC) and squamous cell skin cancers (SCC).
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of skin cancers, surge in improved healthcare infrastructure, rising advancements in skin cancer therapy for developing innovative therapies, increasing demand for development of advanced therapeutics, growing research & development (R&D) activities for cancer therapeutics, and surge in launch of advanced units by market players. For instance, in April 2022, barnaclà¬nic+ has inaugurated its Dermatological Diagnosis Unit, specializing in the diagnosis and therapy of skin cancer. This newly established unit is equipped with state-of-the-art dermatological diagnostic technology for the diagnosis of skin cancer. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in initiative taken by government to develop healthcare infrastructure, growing awareness among people regarding availability of skin care treatments, increase in number of population suffering from melanoma, and rising research & development activities. For instance, in December 2022, Sirnaomics Ltd. has unveiled the interim findings from the initial segment of an ongoing Phase IIb clinical study involving STP705, intended for addressing Cutaneous Squamous Cell Carcinoma In Situ (isSCC). Encouraging clinical outcomes were observed in the preliminary phase of this Phase IIb trial for the compound.
Increasing launch of advanced treatment options is predicted to boost the market growth during the forecast period. A notable trend in the skin cancer treatment market involves the growing utilization of targeted and immunotherapy medications. Chemotherapy and radiation therapy are associated with several adverse effects. Consequently, there is a rising inclination among patients to select immunotherapy and targeted therapy medications. Moreover, targeted therapy drugs offer improved effectiveness in the treatment of skin cancer. For instance, in May 2022, Labcorp, a prominent worldwide life sciences firm, has introduced a novel assay designed to aid in determining suitable treatment choices for melanoma. This innovative test allows for the evaluation of Lymphocyte-activation gene 3 (LAG-3) expression levels through immunohistochemistry (IHC) analysis of tumor tissue. LAG-3 represents a target for immune-oncology and has shown tangible positive outcomes in treating melanoma patients. The assay is applicable for employment in both patient care and treatment as well as in clinical trial settings.
By indication, melanoma was the highest revenue-grossing segment in the global skin cancer treatment market in 2023 owing to rising prevalence of melanoma, increasing awareness regarding skin cancer among population, surge in technological advancement in the healthcare sector, and growing regulatory approvals. For instance, in January 2022, Immunocore has obtained United States Food and Drug Administration (FDA) clearance for KIMMTRAK (tebentafusp-tebn) to treat adult patients with unresectable or metastatic uveal melanoma (mUM) who are HLA-A*02:01-positive. Additionally, non-melanoma is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for surgical procedures & radiation therapy, surge in introduction of immunotherapy drugs against non-melanoma type of skin cancer, rising accessibility of therapeutic drugs for the treatment of non- melanoma, and growing research activities by key market players.
By therapy, immunotherapy was the highest revenue-grossing segment in the global skin cancer treatment market in 2023 owing to the efficacy of immunotherapy & a reduced risk of adverse effects, surge in number of product launches of immunotherapy drugs, and increasing approvals of novel immunotherapies by regulatory bodies. For instance, in March 2022, Nivolumab and Relatlimab-Rmbw (commercially known as Opdualag by Bristol-Myers Squibb Company) have gained the endorsement of the US FDA for treating unresectable or metastatic melanoma in patients aged 12 years and older, covering both adults and pediatric individuals. Additionally, radiation therapy is predicted to grow at fastest CAGR during the forecast period owing to the rising usage in treatment of squamous cell skin cancers and growing technological advancements in radiation therapy.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global skin cancer treatment market in 2023 owing to the ease of availability of drugs in hospital pharmacy and growing number of hospitals with hospital pharmacies. Additionally, online platforms is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of online platforms for buying pharmaceuticals, a rise in public awareness of these platforms, and growing initiatives by leading market players. For instance, in January 2022, SkinCure Oncology has directed its attention toward establishing a comprehensive approach to delivering Image-Guided Superficial Radiotherapy (Image-Guided SRT). They have introduced GentleCure.com, a platform dedicated to consumer health education, which presents well-founded treatment choices for basal cell (BCC) and squamous cell skin cancers (SCC).
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of skin cancers, surge in improved healthcare infrastructure, rising advancements in skin cancer therapy for developing innovative therapies, increasing demand for development of advanced therapeutics, growing research & development (R&D) activities for cancer therapeutics, and surge in launch of advanced units by market players. For instance, in April 2022, barnaclà¬nic+ has inaugurated its Dermatological Diagnosis Unit, specializing in the diagnosis and therapy of skin cancer. This newly established unit is equipped with state-of-the-art dermatological diagnostic technology for the diagnosis of skin cancer. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in initiative taken by government to develop healthcare infrastructure, growing awareness among people regarding availability of skin care treatments, increase in number of population suffering from melanoma, and rising research & development activities. For instance, in December 2022, Sirnaomics Ltd. has unveiled the interim findings from the initial segment of an ongoing Phase IIb clinical study involving STP705, intended for addressing Cutaneous Squamous Cell Carcinoma In Situ (isSCC). Encouraging clinical outcomes were observed in the preliminary phase of this Phase IIb trial for the compound.
Segmentation: Skin Cancer Treatment Market Report 2022 - 2033
Skin Cancer Treatment Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Melanoma
- Non-melanoma
Skin Cancer Treatment Market Analysis & Forecast by Therapy 2023 - 2034 (Revenue USD Bn)
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
Skin Cancer Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacy
- Hospital Pharmacy
- Online Platforms
- Others
Skin Cancer Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Skin Cancer Treatment Market: Indication Estimates & Trend Analysis
8. Skin Cancer Treatment Market: Therapy Estimates & Trend Analysis
9. Skin Cancer Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Skin Cancer Treatment Market
12. Europe Global Skin Cancer Treatment Market
13. Asia Pacific Global Skin Cancer Treatment Market
14. Latin America Global Skin Cancer Treatment Market
15. MEA Global Skin Cancer Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- LEO Pharma
- Merck KGaA
- Sun Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb
- Novartis AG
- Amgen Inc.
- F. Hoffmann-La Roche
- Pfizer Inc.
- GlaxoSmithKline plc
- Regeneron Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 10.73 Billion |
| Forecasted Market Value ( USD | $ 26.65 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
